Trial Profile
Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Tivantinib (Primary) ; Carboplatin; Pemetrexed
- Indications Malignant-mesothelioma; Non-small cell lung cancer
- Focus Adverse reactions
- 20 Jan 2021 Status changed from active, no longer recruiting to completed.
- 09 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
- 20 Jul 2016 Planned End Date changed from 1 Jul 2016 to 1 Dec 2016.